Sphera Funds Management Ltd. Immunovant, Inc. Transaction History

Sphera Funds Management Ltd.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 17, 2021	SELL	$9.4 - $16.85 $1.49 Million - $2.67 Million	-158,500 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$13.08 - $49.6 $150,420 - $570,400	-11,500 Reduced 6.76%	158,500 $2.54 Million
Q3 2020 Nov 12, 2020	BUY	$22.61 - $38.9 $1.47 Million - $2.53 Million	65,000 Added 61.9%	170,000 $5.98 Million
Q2 2020 Aug 13, 2020	BUY	$13.87 - $28.44 $1.19 Million - $2.44 Million	85,968 Added 451.7%	105,000 $2.56 Million
Q1 2020 May 14, 2020	SELL	$8.36 - $17.13 $8,092 - $16,581	-968 Reduced 4.84%	19,032 $296,000
Q4 2019 Feb 13, 2020	BUY	$10.02 - $16.4 $200,400 - $328,000	20,000 New	20,000 $317,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.